Abstract
Radioimmunotherapy relies on the principles of immunotherapy, but expands the cytotoxic effects of the antibody by complexing it with a radiation-emitting particle. If we consider radioimmunotherapy as a step beyond immunotherapy of cancer, the step was prompted by the (relative) failure of the latter. The conventional way to explain the failure is a lack of intrinsic killing effect and a lack of penetration into poorly vascularized tumor masses. The addition of a radioactive label (usually a β-emitter) to the antibody would improve both. Radiation is lethal and the type of radiation used (beta rays) has a sufficient range to overcome the lack of antibody penetration. At present, the most successful (and FDA approved) radioimmunotherapy agents for lymphomas are anti-CD20 monoclonal antibodies. Rituximab (Rituxan®) is a chimeric antibody, used as a non-radioactive antibody and to pre-load the patient when Zevalin® is used. Zevalin® is the Yttrium-90 (90Y) or Indium-111 (111In) labeled form of Ibritumomab Tiuxetan. Bexxar® is the Iodine-131 (131I) labeled form of Tositumomab. Ibritumomab Tiuxetan and Tositumomab are murine anti-CD20 monoclonal antibodies, not chimeric antibodies. Promising research is being done to utilize radioimmunotherapy earlier in the treatment algorithm for lymphoma, including as initial, consolidation, and salvage therapies. However, despite more than 8 years since initial regulatory approval, radioimmunotherapy still has not achieved widespread use due to a combination of medical, scientific, logistic, and financial barriers. Other experimental uses for radioimmunotherapy include other solid tumors to treat infections. Optimization can potentially be done with pre-targeting and bi-specific antibodies. Alpha particle and Auger electron emitters show promise as future radioimmunotherapy agents but are mostly still in pre-clinical stages.
Keywords: Radioimmunotherapy, Zevalin®, Bexxar®, lymphoma, alpha particle, immunotherapy, radiation-emitting particle, cancer, emitter, radioimmunotherapy agents, lymphomas, anti-CD20 monoclonal antibodies, Zevalin, Tositumomab, Ibritumomab, Tiuxetan, Bexxar, dose-limiting myelotoxicity, anti-murine antibody reaction, breast cancer, hepatocellular carcinoma, malignancies, medullary thyroid, prostate cancers, monoclonal antibodies, follicular lymphoma, ofatumumab, anti-vascular endothelial growth factor A, anti-epidermal growth factor receptor, anti-HER2/neu receptor, DNA-repair mechanisms, B-cell lymphoma, rituximab-radionuclide complexes, cellular death, photodynamic therapy, chemotherapy, CD20, FDA-approved RIT agents, myelosuppression, immunocompetency, Hypothyroidism, potassium iodide, non-Hodgkins lymphoma, medullary thyroid cancer, Carcinoembryonic Antigen Target, MUC-1 Antigen
Current Drug Discovery Technologies
Title: Current Concepts and Future Directions in Radioimmunotherapy
Volume: 7 Issue: 4
Author(s): Frank I. Lin and Andrei Iagaru
Affiliation:
Keywords: Radioimmunotherapy, Zevalin®, Bexxar®, lymphoma, alpha particle, immunotherapy, radiation-emitting particle, cancer, emitter, radioimmunotherapy agents, lymphomas, anti-CD20 monoclonal antibodies, Zevalin, Tositumomab, Ibritumomab, Tiuxetan, Bexxar, dose-limiting myelotoxicity, anti-murine antibody reaction, breast cancer, hepatocellular carcinoma, malignancies, medullary thyroid, prostate cancers, monoclonal antibodies, follicular lymphoma, ofatumumab, anti-vascular endothelial growth factor A, anti-epidermal growth factor receptor, anti-HER2/neu receptor, DNA-repair mechanisms, B-cell lymphoma, rituximab-radionuclide complexes, cellular death, photodynamic therapy, chemotherapy, CD20, FDA-approved RIT agents, myelosuppression, immunocompetency, Hypothyroidism, potassium iodide, non-Hodgkins lymphoma, medullary thyroid cancer, Carcinoembryonic Antigen Target, MUC-1 Antigen
Abstract: Radioimmunotherapy relies on the principles of immunotherapy, but expands the cytotoxic effects of the antibody by complexing it with a radiation-emitting particle. If we consider radioimmunotherapy as a step beyond immunotherapy of cancer, the step was prompted by the (relative) failure of the latter. The conventional way to explain the failure is a lack of intrinsic killing effect and a lack of penetration into poorly vascularized tumor masses. The addition of a radioactive label (usually a β-emitter) to the antibody would improve both. Radiation is lethal and the type of radiation used (beta rays) has a sufficient range to overcome the lack of antibody penetration. At present, the most successful (and FDA approved) radioimmunotherapy agents for lymphomas are anti-CD20 monoclonal antibodies. Rituximab (Rituxan®) is a chimeric antibody, used as a non-radioactive antibody and to pre-load the patient when Zevalin® is used. Zevalin® is the Yttrium-90 (90Y) or Indium-111 (111In) labeled form of Ibritumomab Tiuxetan. Bexxar® is the Iodine-131 (131I) labeled form of Tositumomab. Ibritumomab Tiuxetan and Tositumomab are murine anti-CD20 monoclonal antibodies, not chimeric antibodies. Promising research is being done to utilize radioimmunotherapy earlier in the treatment algorithm for lymphoma, including as initial, consolidation, and salvage therapies. However, despite more than 8 years since initial regulatory approval, radioimmunotherapy still has not achieved widespread use due to a combination of medical, scientific, logistic, and financial barriers. Other experimental uses for radioimmunotherapy include other solid tumors to treat infections. Optimization can potentially be done with pre-targeting and bi-specific antibodies. Alpha particle and Auger electron emitters show promise as future radioimmunotherapy agents but are mostly still in pre-clinical stages.
Export Options
About this article
Cite this article as:
I. Lin Frank and Iagaru Andrei, Current Concepts and Future Directions in Radioimmunotherapy, Current Drug Discovery Technologies 2010; 7 (4) . https://dx.doi.org/10.2174/157016310793360684
DOI https://dx.doi.org/10.2174/157016310793360684 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepcidin: Biological Activity, Analytical Methods in Biological Fluids, Clinical Applications and Antagonists. A Short Review
Current Pharmaceutical Analysis Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry The Pharmacokinetics of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Fluoroquinolones Prophylaxis of Bacterial Infections in Neutropenic Patients: Time to Re-Evaluate
Current Cancer Therapy Reviews Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Translational Science: Epistemology and the Investigative Process
Current Genomics Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma
Current Gene Therapy Lung Cancer Stem Cells: An Epigenetic Perspective
Current Cancer Drug Targets Analysis of Key GO Terms and KEGG Pathways Associated with Carcinogenic Chemicals
Combinatorial Chemistry & High Throughput Screening Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy